Printer Friendly

Articles from M2 Pharma (August 3, 2011)

1-7 out of 7 article(s)
Title Author Type Words
BioSante closes USD48m public offering of common stock. 212
Daiichi Sankyo, Ranbaxy to expand hybrid business model in Mexico. 145
EC greenlights Roche's Roactemra for arthritis in children. 112
FDA accepts for filing MAP's LEVADEX NDA. 286
IntelGenx unveils successful FDA pre-approval inspection of CPI-300. 270
Mylan says USPTO intends to reissue two Perforomist patents to Dey Pharma. 217
Pfizer returns rapamycin analogue programme to Biotica. 162

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters